PREDICTIVE VALUE OF SERUM CHEMERIN AND NAFLD FIBROSIS SCORE TO ULTRASONOGRAPHIC DETECTION AND QUANTIFICATION OF STEATOSIS IN NONALCOHOLIC FATTY LIVER DISEASE PATIENTS

Abstract

Non Alcoholic Fatty Liver Disease (NAFLD) is the most prevalent form of chronic liver disease worldwide, affecting as much as 30% of the adult western population and to validate the diagnostic value of serum chemerin, NAFLD Fibrosis and abdominal ultrasound as non-invasive methods for steatosis detection and quantification and screening for NAFLD and determing further need for liver biopsy.

Liver steatosis may predispose the liver to inflammation, fibrosis, and eventually cirrhosis and hepatocellular carcinoma.

Non Alcoholic Fatty Liver Disease (NAFLD) is the most prevalent form of chronic liver disease worldwide, affecting as much as 30% of the adult western population.

NAFLD is considered as the most prevalent chronic liver disease, affecting as much as 30% of the adult western population.

NAFLD is strongly associated with metabolic risk factors such cardiovascular disease, obesity, diabetes mellitus and dyslipidemia.

Liver biopsy is the gold standard for diagnosis and quantification of liver steatosis in NAFLD; however, it is not routinely performed in all NAFLD patients because it is an invasive procedure with potential complications and a significant degree of sampling error.

Therefore noninvasive methods including imaging techniques and blood test based markers have been developed to qualify and quantify liver steatosis.